Vol 3, No 1 (2002): Practical Diabetology
Research paper
Published online: 2001-12-06
Assessment of applicability of NovoNorm as a first line therapy in type 2 diabetes patient in General Practitioner practice
Diabetologia Praktyczna 2002;3(1):9-16.
Abstract
INTRODUCTION. NovoNorm is effective first line treatment in type 2 diabetes.
Its mechanism of action is primarily prandial glucose regulation. This leads to
good tolerance, easy dosing, simple application regimen and less hypoglycemic
reactions. Those features make Novo Norm interesting choice for both patients
and doctors. The aim of this study was the evaluation of the applicability of
NovoNorm in general practitioner practice.
MATERIAL AND METHODS. 25 weeks prospective trial included 168 type 2 diabetes patients and 36 general practitioner practices. Efficacy of Novo Norm wasassessed using endpoints as HbA1c change from baseline, fasting plasma glucose and 7-point glycemia profile. Safety was assessed as the number of hypoglycemic
symptom episodes. Furthermore, adherence to treatment (as an index based on drug accountability and patient diary) and treatment satisfaction from patient (DTSQ questionnaire) and doctor (D-SAT questionnaire) perspective were also assessed.
RESULTS. FPG and HbA1c reduction during 25 weeks of treatment with NovoNorm were not only statistically significant but also clinically relevant. Mean value of FPG during screening visit was 158.96 mg/dl and reduced to 123.29 mg/dl (HbA1c 7.45% to 6.51 respectively). Efficacy of the drug was assessed as high in over 95 responses.
CONCLUSIONS. The results based on doctors and patients evaluation point at the fact that new concept of diabetes treatment namely prandial glucose regulation is fully accepted and NovoNorm is a useful option for treatment of type 2 diabetes.
MATERIAL AND METHODS. 25 weeks prospective trial included 168 type 2 diabetes patients and 36 general practitioner practices. Efficacy of Novo Norm wasassessed using endpoints as HbA1c change from baseline, fasting plasma glucose and 7-point glycemia profile. Safety was assessed as the number of hypoglycemic
symptom episodes. Furthermore, adherence to treatment (as an index based on drug accountability and patient diary) and treatment satisfaction from patient (DTSQ questionnaire) and doctor (D-SAT questionnaire) perspective were also assessed.
RESULTS. FPG and HbA1c reduction during 25 weeks of treatment with NovoNorm were not only statistically significant but also clinically relevant. Mean value of FPG during screening visit was 158.96 mg/dl and reduced to 123.29 mg/dl (HbA1c 7.45% to 6.51 respectively). Efficacy of the drug was assessed as high in over 95 responses.
CONCLUSIONS. The results based on doctors and patients evaluation point at the fact that new concept of diabetes treatment namely prandial glucose regulation is fully accepted and NovoNorm is a useful option for treatment of type 2 diabetes.
Keywords: type 2 diabetesprandial glucose regulation